New data from the ongoing Open-Label Phase III Extension Study of PXT3003, the PLEO-CMT-FU trial, are consistent with a good safety profile and long-term treatment effect of PXT3003 measured on... | May 25, 2023

Related Keywords

United States ,Canada ,Paris ,France General ,France ,Fabreguettes Leib ,Shahram Attarian ,Schwartz ,University Hospital La Timone ,Rare Diseases Network ,Neuromuscular Diseases Reference Centers ,Open Label Phase ,Overall Neuropathy Limitation Scale ,Charcot Marie Tooth Disease Type ,Overall Neuropathy Limitations Scale ,Neuromuscular Diseases ,Diseases Network ,Lead Investigator ,First Double Blind Phase ,Open Label Extension ,Total Trial ,High Dose ,Low Dose ,Label Extension ,Meter Walk Test ,Quantified Muscular Testing ,Patient Global Impression ,Charcot Marie Tooth Neuropathy Score ,Euronext Growth ,Presse Financi ,Pharnext Sa Stock Exchange ,News ,Information ,Press Release ,Few ,Data ,Rom ,The ,Ngoing ,Hase ,Wii ,Extension ,Study ,F ,Fire ,Consistent ,Ith ,Wood ,Safety ,Profile ,End ,Treatment ,Effect ,Xt3003 ,Easured Alpha Fr001400gun7 ,